| Literature DB >> 26785121 |
Sarah L Gorst1, Elizabeth Gargon1, Mike Clarke2, Jane M Blazeby3, Douglas G Altman4, Paula R Williamson1.
Abstract
BACKGROUND: A COS represents an agreed minimum set of outcomes that should be measured and reported in all trials of a specific condition. The COMET (Core Outcome Measures in Effectiveness Trials) initiative aims to collate and stimulate the development and application of COS, by including data on relevant studies within a publically available internet-based resource. In recent years, there has been an interest in increasing the development of COS. Therefore, this study aimed to provide an update of a previous review, and examine the quality of development of COS. A further aim was to understand the reasons why individuals are searching the COMET database.Entities:
Mesh:
Year: 2016 PMID: 26785121 PMCID: PMC4718543 DOI: 10.1371/journal.pone.0146444
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Identification of studies.
Fig 2Year of first publication of each COS study (n = 227).
Fig 3Number of COS developed in each disease category (n = 227).
The scope of included studies (n = 227).
| Original review n (%) | Updated review n (%) | Combined n (%) | |
|---|---|---|---|
| Specifically considered outcome selection and measurement | 97 (49) | 22 (76) | 119 (52%) |
| Considered outcomes while addressing wider clinical trial design issues | 101 (51) | 7 (24) | 108 (48%) |
| Clinical trials | 141 (71) | 19 (66) | 160 (71) |
| Clinical research | 27 (14) | 4 (14) | 31 (14) |
| Clinical research and practice | 11 (6) | 4 (14) | 15 (7) |
| Clinical trials and clinical practice | 10 (5) | 0 (0) | 10 (4) |
| Clinical trials and regulatory purposes | 3 (2) | 0 (0) | 3 (1) |
| Trials and observational studies | 3 (2) | 0 (0) | 3 (1) |
| Clinical trial extension studies | 1 (4) | 1 (<1) | |
| Clinical trials, research and clinical record keeping | 1 (4) | 1 (<1) | |
| Observational studies | 1 (<1) | 0 (0) | 1 (<1) |
| Trials and case series | 1 (<1) | 0 (0) | 1 (<1) |
| Clinical research, clinical practice and regulatory purpose | 1 (<1) | 0 (0) | 1 (<1) |
| Adults | 10 (5) | 11 (38) | 21 (9) |
| Children | 23 (12) | 2 (7) | 25 (11) |
| Adults and children | 13 (7) | 1 (4) | 14 (6) |
| Older adults | 3 (2) | 1 (4) | 4 (2) |
| Adults and neonates | 0 (0) | 1 (4) | 1 (<1) |
| Not specified | 149 (75) | 13 (45) | 162 (71) |
| All intervention types | 7 (4) | 9 (31) | 16 (7) |
| Drug treatments | 40 (20) | 4 (14) | 44 (19) |
| Surgery | 13 (7) | 4 (14) | 17 (8) |
| Vaccine | 2 (1) | 0 (0) | 2 (1) |
| Rehabilitation | 1 (1) | 1 (4) | 2 (1) |
| Exercise | 1 (1) | 1 (4) | 2 (1) |
| Procedure | 5 (3) | 0 (0) | 5 (2) |
| Device | 3 (2) | 0 (0) | 3 (1) |
| Other | 11 (6) | 5 (17) | 16 (7) |
| Not specified | 115 (58) | 5 (17) | 120 (53) |
*Procedure descriptions–
Procedure—Uterine artery embolization.
Procedure—Aortic valve stenosis (AS)—transcatheter aortic valve implantation.
Procedure—Aortic valve stenosis (AS).
Procedure—pulp treatments of primary teeth.
Procedure—drug-eluting coronary stents (DES).
**Device descriptions–
Device–Compression (n = 2).
Device—Mechanical circulatory support (MCS).
***Other descriptions–
Coronary angiogenesis.
Hip protectors.
Neuro-protective therapy (aka Neuroprotection).
Non-surgical treatment (no other detail given).
Operative and non-operative management.
Oral care products.
Ascorbic acid.
Fall injury prevention interventions.
Behavioural therapies or other kinds of nonpharmacologic therapies.
Psychological & behavioural: Psychosocial.
Maternity care.
Complementary and alternative medicine (CAM).
Chemotherapy.
Platelet transfusion trials.
Endovascular therapy.
Constraint-induced movement therapy (CIMT).
Public involvement detail where reported (n = 6).
| Methods used | Total number of participants | Number of public participants | % Public participants | |
|---|---|---|---|---|
| 1 | Meeting and teleconferences (mixed) | 6 | 1 | 17% |
| 2 | Nominal Group Technique (mixed) | 25 | 3 | 12% |
| 3 | Meeting (mixed) | 12 | 1 | 8% |
| 4 | Focus groups (patient only) | 45 | 45 | |
| Delphi (clinician only) | Round 1: 249 | Round 1: 249 | ||
| Round 2: 247 | Round 2: 247 | |||
| Round 3: 247 | Round 3: 247 | |||
| Nominal Group Technique (mixed) | 28 | 5 | 18% | |
| 5 | Delphi (patient only) | Round 1: 169 | Round 1: 169 | |
| Round 2: 152 | Round 2: 152 | |||
| Round 3: 147 | Round 3: 147 | |||
| 6 | Delphi (patient only) | Round 1: 71 | Round 1: 71 | |
| Round 2: 67 | Round 2: 67 | |||
| Round 3: 62 | Round 3: 62 | |||
| Delphi (clinician only) | Round 1: 39 | Round 1: 39 | ||
| Round 2: 35 | Round 2: 35 | |||
| Round 3: 33 | Round 2: 33 | |||
| Round 2: 35 | Round 2: 35 | |||
| Round 3: 33 | Round 2: 33 |
* Patient core set
Results from pop-up survey.
| Reason | N |
|---|---|
| I am thinking about developing a core outcome set | 49 |
| We are considering funding a core outcome set | 3 |
| I am reviewing a funding application for the development of a core outcome set | 0 |
| I have been asked to take part in a core outcome set study | 2 |
| I am a person with a condition | 0 |
| I am planning a systematic review of clinical trials | 19 |
| I am planning a clinical trial | 33 |
| I am reviewing a funding application for a trial | 4 |
| We are considering funding a clinical trial | 2 |
| I am involved in auditing a condition | 6 |
| As part of a general educational activity | 29 |
| General interest | 27 |
| None of the above | 32 |
| Did not respond | 190 |
| 396 |